Less is less: photometry alone cannot predict the observed spectral indices of z∼1z\sim1 galaxies from the LEGA-C spectroscopic survey

We test whether we can predict optical spectra from deep-field photometry of distant galaxies. Our goal is to perform a comparison in data space, highlighting the differences between predicted and observed spectra. The Large Early Galaxy Astrophysics Census (LEGA-C) provides high-quality optical spectra of thousands of galaxies at redshift $0.6<z<1$. Broad-band photometry of the same galaxies, drawn from the recent COSMOS2020 catalog, is used to predict the optical spectra with the spectral energy distribution (SED) fitting code Prospector and the MILES stellar library. The observed and predicted spectra are compared in terms of two age and metallicity-sensitive absorption features (H$\delta_\mathrm{A}$ and Fe4383). The global bimodality of star-forming and quiescent galaxies in photometric space is recovered with the model spectra. But the presence of a systematic offset in the Fe4383 line strength and the weak correlation between the observed and modeled line strength imply that accurate age or metallicity determinations cannot be inferred from photometry alone. For now we caution that photometry-based estimates of stellar population properties are determined mostly by the modeling approach and not the physical properties of galaxies, even when using the highest-quality photometric datasets and state-of-the-art fitting techniques. When exploring a new physical parameter space (i.e. redshift or galaxy mass) high-quality spectroscopy is always needed to inform the analysis of photometry.Comment: 13 pages, 8 figures, accepted 26 October 202

Stellar Half-Mass Radii of 0.5<z<2.30.5<z<2.3 Galaxies: Comparison with JWST/NIRCam Half-Light Radii

We use CEERS JWST/NIRCam imaging to measure rest-frame near-IR light profiles of $>$500 $M_\star>10^{10}~M_\odot$ galaxies in the redshift range $0.5<z<2.3$. We compare the resulting rest-frame 1.5-2$\mu$m half-light radii ($R_{\rm{NIR}}$) with stellar half-mass radii (\rmass) derived with multi-color light profiles from CANDELS HST imaging. In general agreement with previous work, we find that $R_{\rm{NIR}}$ and \rmass~are up to 40\%~smaller than the rest-frame optical half-light radius $R_{\rm{opt}}$. The agreement between $R_{\rm{NIR}}$ and \rmass~is excellent, with negligible systematic offset ($<$0.03 dex) up to $z=2$ for quiescent galaxies and up to $z=1.5$ for star-forming galaxies. We also deproject the profiles to estimate \rmassd, the radius of a sphere containing 50\% of the stellar mass. We present the $R-M_\star$ distribution of galaxies at $0.5<z<1.5$, comparing $R_{\rm{opt}}$, \rmass~and \rmassd. The slope is significantly flatter for \rmass~and \rmassd~ compared to $R_{\rm{opt}}$, mostly due to downward shifts in size for massive star-forming galaxies, while \rmass~and \rmassd~do not show markedly different trends. Finally, we show rapid size evolution ($R\propto (1+z)^{-1.7\pm0.1}$) for massive ($M_\star>10^{11}~M_\odot$) quiescent galaxies between $z=0.5$ and $z=2.3$, again comparing $R_{\rm{opt}}$, \rmass~and \rmassd. We conclude that the main tenets of the size evolution narrative established over the past 20 years, based on rest-frame optical light profile analysis, still hold in the era of JWST/NIRCam observations in the rest-frame near-IR.Comment: Submitted to ApJ. Comments welcom

Anti-NMDAR Encephalitis in the Netherlands, Focusing on Late-Onset Patients and Antibody Test Accuracy

BACKGROUND AND OBJECTIVES: To describe the clinical features of anti-NMDAR encephalitis, emphasizing on late-onset patients and antibody test characteristics in serum and CSF. METHODS: Nationwide observational Dutch cohort study, in patients diagnosed with anti-NMDAR encephalitis between 2007 and 2019. RESULTS: One hundred twenty-six patients with anti-NMDAR encephalitis were included with a median age of 24 years (range 1-86 years). The mean annual incidence was 1.00/million (95% CI 0.62-1.59). Patients ≥45 years of age at onset (19%) had fewer seizures (46% vs 71%, p = 0.021), fewer symptoms during disease course (3 vs 6 symptoms, p = 0.020), and more often undetectable serum antibodies compared with younger patients (p = 0.031). In the late-onset group, outcome was worse, and all tumors were carcinomas (both p < 0.0001). CSF was more accurate than serum to detect anti-NMDAR encephalitis (sensitivity 99% vs 68%, p < 0.0001). Using cell-based assay (CBA), CSF provided an unconfirmed positive test result in 11/2,600 patients (0.4%); 6/11 had a neuroinflammatory disease (other than anti-NMDAR encephalitis). Patients with anti-NMDAR encephalitis, who tested positive in CSF only, had lower CSF antibody titers (p = 0.003), but appeared to have an equally severe disease course. DISCUSSION: Anti-NMDAR encephalitis occurs at all ages and is less rare in the elderly patients than initially anticipated. In older patients, the clinical phenotype is less outspoken, has different tumor association, and a less favorable recovery. Detection of antibodies in CSF is the gold standard, and although the CBA has very good validity, it is not perfect. The clinical phenotype should be leading, and confirmation in a research laboratory is recommended, when in doubt

Shaping of the Present-Day Deep Biosphere at Chicxulub by the Impact Catastrophe That Ended the Cretaceous

We report on the effect of the end-Cretaceous impact event on the present-day deep microbial biosphere at the impact site. IODP-ICDP Expedition 364 drilled into the peak ring of the Chicxulub crater, México, allowing us to investigate the microbial communities within this structure. Increased cell biomass was found in the impact suevite, which was deposited within the first few hours of the Cenozoic, demonstrating that the impact produced a new lithological horizon that caused a long-term improvement in deep subsurface colonization potential. In the biologically impoverished granitic rocks, we observed increased cell abundances at impact-induced geological interfaces, that can be attributed to the nutritionally diverse substrates and/or elevated fluid flow. 16S rRNA gene amplicon sequencing revealed taxonomically distinct microbial communities in each crater lithology. These observations show that the impact caused geological deformation that continues to shape the deep subsurface biosphere at Chicxulub in the present day

The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies

In this study we report the clinical features of 32 patients with gamma aminobutyric acid B receptor (GABABR) antibodies, identify additional autoantibodies in patients with anti-GABABR encephalitis that mark the presence of an underlying small cel

Global overview of the management of acute cholecystitis during the COVID-19 pandemic (CHOLECOVID study)

Background: This study provides a global overview of the management of patients with acute cholecystitis during the initial phase of the COVID-19 pandemic. Methods: CHOLECOVID is an international, multicentre, observational comparative study of patients admitted to hospital with acute cholecystitis during the COVID-19 pandemic. Data on management were collected for a 2-month study interval coincident with the WHO declaration of the SARS-CoV-2 pandemic and compared with an equivalent pre-pandemic time interval. Mediation analysis examined the influence of SARS-COV-2 infection on 30-day mortality. Results: This study collected data on 9783 patients with acute cholecystitis admitted to 247 hospitals across the world. The pandemic was associated with reduced availability of surgical workforce and operating facilities globally, a significant shift to worse severity of disease, and increased use of conservative management. There was a reduction (both absolute and proportionate) in the number of patients undergoing cholecystectomy from 3095 patients (56.2 per cent) pre-pandemic to 1998 patients (46.2 per cent) during the pandemic but there was no difference in 30-day all-cause mortality after cholecystectomy comparing the pre-pandemic interval with the pandemic (13 patients (0.4 per cent) pre-pandemic to 13 patients (0.6 per cent) pandemic; P = 0.355). In mediation analysis, an admission with acute cholecystitis during the pandemic was associated with a non-significant increased risk of death (OR 1.29, 95 per cent c.i. 0.93 to 1.79, P = 0.121). Conclusion: CHOLECOVID provides a unique overview of the treatment of patients with cholecystitis across the globe during the first months of the SARS-CoV-2 pandemic. The study highlights the need for system resilience in retention of elective surgical activity. Cholecystectomy was associated with a low risk of mortality and deferral of treatment results in an increase in avoidable morbidity that represents the non-COVID cost of this pandemic

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase&nbsp;1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation&nbsp;disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age&nbsp; 6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score&nbsp; 652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc&nbsp;= 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N&nbsp;= 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in&nbsp;Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in&nbsp;Asia&nbsp;and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701